Latest revenue
$139.1M
as of 2026-03-31
Latest net income
$28.7M
as of 2026-03-31
Net margin
20.6%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $3.59B
- Enterprise value
- $3.59B
- P/E (trailing)
- 54.2×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $50.71
- 52-wk low
- $22.61
- Beta
- —
- Shares out
- 79.8M
5-year trend
What this company does
ITEM 1. BUSINESS General At Veracyte, we believe that exceptional cancer care begins with exceptional diagnostics. We are a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic and predictive treatment decisions. Insights from these tests help patients avoid unnecessary procedures and interventions and accelerate time to appropriate treatment, thereby improving outcomes for patients across our global markets. Through our leading portfolio of comprehensive molecular diagnostic…
AI summary unavailable — showing raw filing excerpt
Generated from VCYT's filing dated 2026-02-26
Key risks
Table of Contents ITEM 1A. RISK FACTORS Summary of Risk Factors Investing in our common stock involves a high degree of risk. You should carefully review the “Risk Factors” section before you invest in shares of our common stock. Listed below are some of the more significant risks relating to an investment in our common stock. Risks Related to Our Business •Our financial results currently depend mainly on sales of our Decipher Prostate and Afirma tests, and we may not generate sufficient revenue from these and our other diagnostic tests to grow our business. •If we are unable to grow sales of our tests or products, or we are unable to launch or commercialize our new tests or products, our…
AI summary unavailable — showing raw filing excerpt
Generated from VCYT's filing dated 2026-02-26
Profitability
Gross margin
70.1%
4.8%Operating margin
11.2%
208.5%Net margin
12.8%
136.9%Return on equity
5.1%
146.8%Return on assets
4.7%
154.2%Leverage
Debt / equity
0.07×
30.2%Long-term debt / equity
0.00×
Debt / assets
6.9%
28.1%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $139.1M | +21.5% | $28.7M | +307.4% | 20.6% |
Q4 2025 2025-12-31 | $140.6M | +18.5% | $41.1M | +489.8% | 29.3% |
Q3 2025 2025-09-30 | $131.9M | +13.8% | $19.1M | +26.3% | 14.5% |
Q2 2025 2025-06-30 | $130.2M | +13.8% | $-980.0K | -125.3% | -0.8% |
Q1 2025 2025-03-31 | $114.5M | +18.2% | $7.0M | +478.1% | 6.2% |
Q4 2024 2024-12-31 | $118.6M | — | $7.0M | — | 5.9% |
Q3 2024 2024-09-30 | $115.9M | +28.6% | $15.2M | +151.2% | 13.1% |
Q2 2024 2024-06-30 | $114.4M | +26.7% | $3.9M | +146.1% | 3.4% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Services-Medical Laboratories · SIC 8071
Your notes
Keep private notes on VCYT — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$12.3M
Net activity
−$12.3M
Distinct insiders
11
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns VCYT
Institutional value
$1.59B
Total shares held
51.2M
Distinct holders
206
-122 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 13.2M | $424.3M | +43.8K (+0.3%) | Added |
| 2 | Artisan Partners Limited Partnership | 5.5M | $177.0M | -766.7K (-12.2%) | Trimmed |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.4M | $143.2M | — | New |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 3.5M | $113.8M | — | New |
| 5 | ARK Investment Management LLC | 3.1M | $98.4M | -833.7K (-21.4%) | Trimmed |
| 6 | DIMENSIONAL FUND ADVISORS LP | 2.9M | $92.8M | +80.6K (+2.9%) | Added |
| 7 | FIRST TRUST ADVISORS LP | 2.1M | $68.2M | +833.5K (+64.9%) | Added |
| 8 | Sumitomo Mitsui Trust Group, Inc. | 1.1M | $34.0M | -202.2K (-16.1%) | Trimmed |
| 9 | Nikko Asset Management Americas, Inc. | 1.0M | $33.6M | -212.9K (-16.9%) | Trimmed |
| 10 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 989.7K | $31.9M | +199.3K (+25.2%) | Added |
| 11 | Legal & General Group Plc | 897.2K | $28.9M | +206.4K (+29.9%) | Added |
| 12 | Fisher Asset Management, LLC | 736.3K | $23.7M | -59.4K (-7.5%) | Trimmed |
| 13 | VANGUARD FIDUCIARY TRUST CO | 548.2K | $17.7M | — | New |
| 14 | PRINCIPAL FINANCIAL GROUP INC | 476.7K | $15.4M | +11.3K (+2.4%) | Added |
| 15 | JPMORGAN CHASE & CO | 496.2K | $15.1M | -23.9K (-4.6%) | Trimmed |
| 16 | Invesco Ltd. | 436.6K | $14.1M | +45.8K (+11.7%) | Added |
| 17 | NEW YORK STATE COMMON RETIREMENT FUND | 421.6K | $13.6M | -164.6K (-28.1%) | Trimmed |
| 18 | SEI INVESTMENTS CO | 420.1K | $13.5M | +34.3K (+8.9%) | Added |
| 19 | Bank of New York Mellon Corp | 413.4K | $13.3M | -13.1K (-3.1%) | Trimmed |
| 20 | BNP PARIBAS FINANCIAL MARKETS | 362.8K | $11.7M | +10.2K (+2.9%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once VCYT's latest filing finishes processing.